HER3 Is an Actionable Target in Advanced Prostate Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is commonly highly expressed in lethal prostate cancer, associating with reduced time to castration resistance (CR) and survival. Multiplex immunofluorescence indicated that the HER3 ligand NRG1 is detectable primarily in tumor-infiltrating myelomonocytic cells in human prostate cancer; this observation was confirmed using single-cell RNA sequencing of human prostate cancer biopsies and murine transgenic prostate cancer models. In castration-resistant prostate cancer (CRPC) patient-derived xenograft organoids with high HER3 expression as well as mouse prostate cancer organoids, recombinant NRG1 enhanced proliferation and survival. Supernatant from murine bone marrow–derived macrophages and myeloid-derived suppressor cells promoted murine prostate cancer organoid growth in vitro, which could be reversed by a neutralizing anti-NRG1 antibody and ERBB inhibition. Targeting HER3, especially with the HER3-directed antibody–drug conjugate U3-1402, exhibited antitumor activity against HER3-expressing prostate cancer. Overall, these data indicate that HER3 is commonly overexpressed in lethal prostate cancer and can be activated by NRG1 secreted by myelomonocytic cells in the tumor microenvironment, supporting HER3-targeted therapeutic strategies for treating HER3-expressing advanced CRPC. Significance: HER3 is an actionable target in prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical evaluation in prospective trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies have demonstrated that HER3 is frequently overexpressed in lethal prostate cancer, where it is associated with more aggressive disease, reduced time to castration resistance, and poor prognosis175.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [175]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116 · cited 1×
“Gene expression, fragments per kilobase of transcript per million mapped reads (FPKM), was calculated using Cufflinks (30).”
MethodSlamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 2×
“Targeting ERBB signaling in clinical trials has to date failed to impart patient bene fi t, perhaps due to feedback loops, continued AR signaling, or insuf fi cient blockade of the entire ERBB axis (9, 10).”
BackgroundSCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction
McInnes, L., Healy, J., & Melville, J. (2018) · arXiv · doi:10.48550/arxiv.1802.03426 · Cited by 7,101 · cited 1×
“We used the Uniform Manifold Approximation and Projection (UMAP) to display cells on a two-dimensional space (26, 27).”
MethodUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
From Louvain to Leiden: guaranteeing well-connected communities
Traag, V. A., Waltman, L., & van Eck, N. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-41695-z · Cited by 5,635 · cited 1×
“We performed clustering analysis using the Leiden algo-rithm with resolution parameter set to 0.15 (22).”
MethodInfluentialDimensionality reduction for visualizing single-cell data using UMAP
Becht, E., McInnes, L., Healy, J., Dutertre, C.-A., Kwok, I. W. H., Ng, L. G., Ginhoux, F., & Newell, E. W. (2019) · Nature Biotechnology · doi:10.1038/nbt.4314 · Cited by 5,358 · cited 1×
“We used the Uniform Manifold Approximation and Projection (UMAP) to display cells on a two-dimensional space (26, 27).”
MethodAran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984 · cited 2×
“Wenowprovide strong evidence to further validate HER3 as a therapeutic target for the treatment of advanced prostate cancer, demonstrating that: (i) its overexpression associates with poorer time to castration resistance and worse OS and higher Ki67; 2) confirming that androgen deprivation can increase HER3 phosphoryl…”
BackgroundMethodAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“While these trials predated the identification of continued AR signaling as a cause of castration resistance, and clinical studies with abiraterone and enzalutamide (42), they discredited targeting ERBB signaling as a therapeutic strategy forCRPC.”
BackgroundSelf-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Self-citation
Cited by
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
“It restored their responsiveness to anti-androgenic therapy [418, 419].”
BackgroundTumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Guo, C. W., Sharp, A., Gürel, B., Crespo, M., Figueiredo, I., Jain, S., Vogl, U. M., Rekowski, J., Rouhifard, M., Gallagher, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06696-z · Cited by 160
“Several groups have shown, using prostate cancer mouse models, that intratumour myeloid cells can drive paracrine oncogenic signalling, senescence evasion and Article immunosuppression 10–12,14– 17 .”
BackgroundSelf-citationB7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Guo, C. W., Figueiredo, I., Gürel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J. C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.09.004 · Cited by 120
Self-citationBreast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 84
Metadata
- Authors
- Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., Clarke, M., Pereira, R., Flohr, P., Fowler, G., Boysen, G., Sumanasuriya, S., Bianchini, D., Rescigno, P., Aversa, C., Tunariu, N., Guo, C., Paschalis, A., Bertan, C., Buroni, L., Ning, J., Carreira, S., Workman, P., Swain, A., Califano, A., Shen, M. M., Alimonti, A., Neeb, A., PCF/SU2C International Prostate Cancer Dream Team, Welti, J., Yuan, W., & de Bono, J.
- Affiliations
- Institute of Cancer Research (GB)
- 1The Institute of Cancer Research, London, United Kingdom.
- Institute of Oncology Research (CH)
- Columbia University (US)
- ORCID
- Gil, Veronica
- Miranda, Susana
- Gurel, Bora
- Vasciaveo, Alessandro
- Crespo, Mateus
- Brina, Daniela
- Dolling, David
- Rekowski, Jan
- Flohr, Penny
- Boysen, Gunther
- Sumanasuriya, Semini
- Rescigno, Pasquale
- Tunariu, Nina
- Guo, Christina
- Paschalis, Alec
- Carreira, Suzanne
- Workman, Paul
- Califano, Andrea
- Shen, Michael M.
- Alimonti, Andrea
- Neeb, Antje
- de Bono, Johann
- Venue
- Cancer Research
- Published
- 2021-11-09
- Volume
- 81
- Issue
- 24
- Pages
- 6207-6218
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC8932336
- OpenAlex
- W3214083702
- Cited by
- 68
- References
- 49
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 19 · 2023: 14 · 2022: 7
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Research (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Prostate Cancer UK (CEO13-3-002, TLD-PF19-005)
- U.S. Department of Defense (W81XWH19-1-0337)
- Prostate Cancer Foundation (20131017, 20131017-1)
- Stand Up To Cancer (SU2C-AACR-DT0712)
- Cancer Research UK (CRM108X-A25144)
- Imperial Experimental Cancer Medicine Centre (ECMC-CRM064X)
- Daiichi Sankyo Company
- Medical Research Council
- Wellcome Trust Centre for Mitochondrial Research
- Chordoma Foundation
- Mark Foundation For Cancer Research
- Academy of Medical Sciences
- National Cancer Institute (R35 CA197745)
- National Institutes of Health (R01 CA251527)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER3, advanced prostate cancer, castration-resistant prostate cancer, neuregulin-1, ErbB signaling, myelomonocytic cells, tumor microenvironment, macrophages, myeloid-derived suppressor cells, patient-derived xenografts
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Camptothecin, Follow-Up Studies, Humans, Male, Organoids, Prognosis, Prospective Studies, Prostatic Neoplasms, Tumor Cells, Cultured, Biomarkers, Tumor, Survival Rate, Mice, SCID, Mice, Inbred NOD, Apoptosis, Neuregulin-1, Receptor, ErbB-3, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Tumor Microenvironment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER3 Is an Actionable Target in Advanced Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-3360
- The paper
- Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., . . . de Bono, J. (2021). HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-3360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.